In vitro evaluation of combined hyperthermia and photodynamic effects using magnetoliposomes loaded with cucurbit[7]uril zinc phthalocyanine complex on melanoma

The aims of this study were two fold; to develop magnetoliposomes (MLs) loaded with zinc phthalocyanine (ZnPc) complexed with cucurbituril (CB) (CB:ZnPc-MLs) and to evaluate their in vitro photodynamic (PD) and/or hyperthermia (HT) effects while using melanoma cells (B16-F10) as model. The liposomal formulations were characterized by both average diameter and zeta potential. The vesicle average size ranged from 150 to 200 nm and the polydispersity index (PdI) from 0.093 to 0.230. The zeta potential was significantly positive with values between 48 and 57 mV. The cell viability (CV) after PD and HT treatments was assessed by colorimetric MTI method. Melanoma cells were initially treated with the liposome formulation without light and magnetic field application, revealing cell viability not different from the control cells (p > 0.05). Photodynamic and hyperthermia assays were also applied separately, demonstrating that PD is more effective than HT in reducing the CV of the neoplastic cells. Combined application of both PD and HT treatments was even more effective in reducing the CV of B16-F10 cells. At the highest light dose (2 J/cm(2)) and under magnetic field activation the CV was about half than PD applied alone. Therefore, the use of the photosensitizer-loaded magnetoliposome for combined photodynamic therapy (PDT) and magnetohyperthermia (MHT) application can be considered as a potential tool to treat malignant melanoma. (C) 2012 Elsevier B.V. All rights reserved.

Study of apoptotic deletion mediated by Bifidobacterium longum with construction of recombinant strains for Serpin encoding gene and phenotypes comparison in a pig cell model

The first part of the research project of the Co-Advisorship Ph.D Thesis was aimed to select the best Bifidobacterium longum strains suitable to set the basis of our study. We were looking for strains with the abilities to colonize the intestinal mucosa and with good adhesion capacities, so that we can test these strains to investigate their ability to induce apoptosis in “damaged” intestinal cells. Adhesion and apoptosis are the two process that we want to study to better understand the role of an adhesion protein that we have previously identified and that have top scores homologies with the recent serpin encoding gene identified in B. longum by Nestlè researchers. Bifidobacterium longum is a probiotic, known for its beneficial effects to the human gut and even for its immunomodulatory and antitumor activities. Recently, many studies have stressed out the intimate relation between probiotic bacteria and the GIT mucosa and their influence on human cellular homeostasis. We focused on the apoptotic deletion of cancer cells induced by B. longum. This has been valued in vitro, performing the incubation of three B.longum strains with enterocyte-like Caco- 2 cells, to evidence DNA fragmentation, a cornerstone of apoptosis. The three strains tested were defined for their adhesion properties using adhesion and autoaggregation assays. These features are considered necessary to select a probiotic strain. The three strains named B12, B18 and B2990 resulted respectively: “strong adherent”, “adherent” and “non adherent”. Then, bacteria were incubated with Caco-2 cells to investigate apoptotic deletion. Cocultures of Caco-2 cells with B. longum resulted positive in DNA fragmentation test, only when adherent strains were used (B12 and B18). These results indicate that the interaction with adherent B. longum can induce apoptotic deletion of Caco-2 cells, suggesting a role in cellular homeostasis of the gastrointestinal tract and in restoring the ecology of damaged colon tissues. These results were used to keep on researching and the strains tested were used as recipient of recombinant techniques aimed to originate new B.longum strains with enhanced capacity of apoptotic induction in “damaged” intestinal cells. To achieve this new goal it was decided to clone the serpin encoding gene of B. longum, so that we can understand its role in adhesion and apoptosis induction. Bifidobacterium longum has immunostimulant activity that in vitro can lead to apoptotic response of Caco-2 cell line. It secretes a hypothetical eukaryotic type serpin protein, which could be involved in this kind of deletion of damaged cells. We had previously characterised a protein that has homologies with the hypothetical serpin of B. longum (DD087853). In order to create Bifidobacterium serpin transformants, a B. longum cosmid library was screened with a PCR protocol using specific primers for serpin gene. After fragment extraction, the insert named S1 was sub-cloned into pRM2, an Escherichia coli - Bifidobacterium shuttle vector, to construct pRM3. Several protocols for B. longum transformation were performed and the best efficiency was obtained using MRS medium and raffinose. Finally bacterial cell supernatants were tested in a dotblot assay to detect antigens presence against anti-antitrypsin polyclonal antibody. The best signal was produced by one starin that has been renamed B. longum BLKS 7. Our research study was aimed to generate transformants able to over express serpin encoding gene, so that we can have the tools for a further study on bacterial apoptotic induction of Caco-2 cell line. After that we have originated new trasformants the next step to do was to test transformants abilities when exposed to an intestinal cell model. In fact, this part of the project was achieved in the Department of Biochemistry of the Medical Faculty of the University of Maribor, guest of the abroad supervisor of the Co-Advisorship Doctoral Thesis: Prof. Avrelija Cencic. In this study we examined the probiotic ability of some bacterial strains using intestinal cells from a 6 years old pig. The use of intestinal mammalian cells is essential to study this symbiosis and a functional cell model mimics a polarised epithelium in which enterocytes are separated by tight junctions. In this list of strains we have included the Bifidobacterium longum BKS7 transformant strain that we have previously originated; in order to compare its abilities. B. longum B12 wild type and B. longum BKS7 transformant and eight Lactobacillus strains of different sources were co-cultured with porcine small intestine epithelial cells (PSI C1) and porcine blood monocytes (PoM2) in Transwell filter inserts. The strains, including Lb. gasseri, Lb. fermentum, Lb. reuterii, Lb. plantarum and unidentified Lactobacillus from kenyan maasai milk and tanzanian coffee, were assayed for activation of cell lines, measuring nitric oxide by Griess reaction, H202 by tetramethylbenzidine reaction and O2 - by cytochrome C reduction. Cytotoxic effect by crystal violet staining and induction on metabolic activity by MTT cell proliferation assay were tested too. Transepithelial electrical resistance (TER) of polarised PSI C1 was measured during 48 hours co-culture. TER, used to observe epithelium permeability, decrease during pathogenesis and tissue becomes permeable to ion passive flow lowering epithelial barrier function. Probiotics can prevent or restore increased permeability. Lastly, dot-blot was achieved against Interleukin-6 of treated cells supernatants. The metabolic activity of PoM2 and PSI C1 increased slightly after co-culture not affecting mitochondrial functions. No strain was cytotoxic over PSI C1 and PoM2 and no cell activation was observed, as measured by the release of NO2, H202 and O2 - by PoM2 and PSI C1. During coculture TER of polarised PSI C1 was two-fold higher comparing with constant TER (~3000 ) of untreated cells. TER raise generated by bacteria maintains a low permeability of the epithelium. During treatment Interleukin-6 was detected in cell supernatants at several time points, confirming immunostimulant activity. All results were obtained using Lactobacillus paracasei Shirota e Carnobacterium divergens as controls. In conclusion we can state that both the list of putative probiotic bacteria and our new transformant strain of B. longum are not harmful when exposed to intestinal cells and could be selected as probiotics, because can strengthen epithelial barrier function and stimulate nonspecific immunity of intestinal cells on a pig cell model. Indeed, we have found out that none of the strains tested that have good adhesion abilities presents citotoxicity to the intestinal cells and that non of the strains tested can induce cell lines to produce high level of ROS, neither NO2. Moreover we have assayed even the capacity of producing certain citokynes that are correlated with immune response. The detection of Interleukin-6 was assayed in all our samples, including B.longum transformant BKS 7 strain, this result indicates that these bacteria can induce a non specific immune response in the intestinal cells. In fact, when we assayed the presence of Interferon-gamma in cells supernatant after bacterial exposure, we have no positive signals, that means that there is no activation of a specific immune response, thus confirming that these bacteria are not recognize as pathogen by the intestinal cells and are certainly not harmful for intestinal cells. The most important result is the measure of Trans Epithelial Electric Resistance that have shown how the intestinal barrier function get strengthen when cells are exposed to bacteria, due to a reduction of the epithelium permeability. We have now a new strain of B. longum that will be used for further studies above the mechanism of apoptotic induction to “damaged cells” and above the process of “restoring ecology”. This strain will be the basis to originate new transformant strains for Serpin encoding gene that must have better performance and shall be used one day even in clinical cases as in “gene therapy” for cancer treatment and prevention.

Untersuchungen zur Lymphozytotoxizität gegen Tumoren in Nierenzellkarzinom-Patienten und HLA-kompatiblen gesunden Spendern

In der vorliegenden Arbeit wurden Blutlymphozyten, die aus allogenen, serologisch HLA (humanes Leukozytenantigen)-identischen gesunden Geschwisterspendern von Nierenzellkarzinom (RCC, engl. renal cell carcinoma)-Patienten isoliert wurden, auf ihre antitumorale Reaktivität in vitro untersucht. Dazu war die vorangehende Generierung von stabil in vitro wachsenden Tumorzelllinien der Patienten zwingende Voraussetzung. Insgesamt wurden aus primärem Tumorgewebe von 65 Nierenzellkarzinom-Patienten Tumorzellen isoliert und daraus Zellkulturen angelegt. In 28 % der Fälle gelang es, eine konstant in Zellkultur wachsende Tumorzelllinie zu etablieren. Daneben wurden aus 56 Tumorpatienten auch die aus dem angrenzenden Nierengewebe gewonnenen nicht-malignen Nierenzellen über wenige Zellkultur-Passagen expandiert. In vier Patienten mit stabil in vitro wachsender Tumorzelllinie war ein allogener HLA-identischer Geschwisterspender verfügbar. In diesen Modellsystemen wurden in gemischten Lymphozyten-Tumorzell-Kulturen (MLTCs, engl. mixed lymphocyte tumor cell cultures) die Blutlymphozyten der Patienten und der gesunden Geschwisterspender mit der jeweiligen Nierenzellkarzinom-Zelllinie stimuliert und tumorreaktive CD8+ zytotoxische T-Lymphozyten (CTLs, engl. cytotoxic T-lymphocytes) generiert. Wenn möglich wurden aus den so gewonnenen „Responder“-Massenkulturen CD8+ T-Zellklone isoliert und hinsichtlich ihrer Funktionalität in IFN-γ-ELISpot-Assays und 51Chrom-Zytotoxizitätstests untersucht. Durch Blockade der HLA-Moleküle mit monoklonalen Antikörpern wurden die HLA-Restriktionselemente sowie weitere an der Erkennung beteiligte Oberflächenmoleküle analysiert. Kreuzreaktivitätsuntersuchungen mit einem breiten Zielzell-„Panel“ gaben Aufschluss über die Reaktivität der CTLs gegen RCC, nicht-maligne Nierenzellen, hämatopoetische Zielzellen von Patient und Geschwisterspender und weitere Tumorzelllinien aus Nierenzellkarzinomen und anderen Tumorentitäten. Interessanterweise zeigten die Geschwister-MLTC-„Responder“-Lymphozyten im Vergleich zu den autologen MLTC-„Responder“-Lymphozyten eine stärkere Proliferation und Zytotoxizität nach Stimulation mit Tumorzellen. Die allogenen tumorreaktiven „Responder“-Lymphozyten entstammten der CD8+ CD62L(high)+ Subpopulation, die naive Vorläufer- und „central memory“-T-Zellen enthält. Im Gegensatz zu autologen MLTC-Lymphozyten und tumorinfiltrierenden Lymphozyten konnte aus nahezu allen allogenen MLTCs mithilfe des Grenzverdünnungsverfahrens ein breites Spektrum an tumorreaktiven CTL-Klonen expandiert werden. Diese lysierten entweder ausschließlich die autologe RCC-Zelllinie oder kreuzreagierten mit autologen nicht-malignen Nierenzellen. Eine Minderheit der CTL-Klone erkannte außerdem hämatopoetische Zellen des Patienten oder allogene Tumorzellen. Als HLA-Restriktionselemente der allogenen tumorreaktiven CD8+ CTL-Klone wurden HLA-A2, -A3, -A11, -A24 und -B7 identifiziert. Weiterhin wurden in einem Modellsystem bisher unbekannte, stark proliferierende CD3+ CD16+ CD57+ CTL-Klone mit nicht-HLA-restringierter Tumorreaktivität isoliert. Zusammenfassend zeigt diese Arbeit erstmals, dass allogene Blutlymphozyten von HLA-identischen gesunden Geschwistern eine Vielfalt von tumorreaktiven CD8+ CTL-Klonen enthalten. Im direkten Vergleich mit autologen Blutlymphozyten der betroffenen Patienten besitzen allogene Blutlymphozyten der Geschwister eine stärkere proliferative und zytotoxische Tumorreaktivität. Die Ergebnisse dieser Arbeit ermutigen weitere Bemühungen, tumorreaktive T-Zellen aus dem Blut von HLA-identischen gesunden Geschwisterspendern in vitro zu generieren. Solche T-Zellen wären in zweierlei Hinsicht von Interesse: Zum einen ermöglichen sie die Identifizierung der Zielantigene, die von T-Zellen aus gesunden Individuen auf Tumoren erkannt werden und als Zielstrukturen von antigenspezifischen Immuntherapien (z. B. Vakzination) dienen könnten. Zum anderen könnten diese T-Zellen möglicherweise für eine adoptive Immuntherapie der betroffenen Tumorpatienten verwendet werden.

Studio di classi di sferoidi multicellulari di carcinoma polmonare epidermoidale in radiobiologia

Il tumore del polmone rappresenta la prima causa di morte nei paesi industrializzati. Le possibilità di trapianto ed intervento chirurgico risultano molto limitate pertanto lo standard di cura risulta essere la radioterapia, a volte abbinata alla chemioterapia. Sebbene trattando radioterapicamente il tumore si ottengano ottimi risultati, attualmente non esistono solide linee guida per la personalizzazione del trattamento al paziente. Il poter eseguire in laboratorio test radioterapici su un elevato numero di campioni risulterebbe un valido approccio sperimentale d’indagine, ma la carenza di materiale su cui poter condurre gli esperimenti limita questa possibilità. Tipicamente, per ovviare al problema vengono utilizzati sferoidi multicellulari tridimensionali creati in laboratorio partendo da singole cellule del tumore in esame. In particolare, l’efficacia del trattamento viene tipicamente correlata alla riduzione volumetrica media stimata utilizzando un set di sferoidi teoricamente identici. In questo studio vengono messe in discussione la validità delle affermazioni tipicamente sostenute attraverso l’analisi di volumi medi. Abbiamo utilizzando un set di circa 100 sferoidi creati in laboratorio partendo da singole cellule di carcinoma epidermoidale polmonare e trattati secondo sette differenti modalità di trattamento radioterapico (variando intensità di radiazione e numero di frazioni). In una prima fase abbiamo analizzato le singole immagini, acquisite al microscopio ottico circa ogni 48 ore, per identificare features morfometriche significative da affiancare all’analisi volumetrica. Sulla base dell’andamento temporale di queste features abbiamo suddiviso gli sferoidi in sottoclassi con evoluzioni completamente differenti che fanno supporre un differente “stato” biologico. Attraverso algoritmi di estrazione di features e classificazione e analizzando riduzione volumetrica, grado di frastagliatura del bordo e quantità di cellule liberate nel terreno di coltura abbiamo definito un protocollo per identificare in maniera automatica le sottopopolazioni di sferoidi. Infine, abbiamo ricercato con successo alcune features morfometriche in grado di predire, semplicemente analizzando immagini acquisite nei giorni seguenti all’ultimo trattamento, lo “stato di salute” del tumore a medio/lungo periodo. Gli algoritmi realizzati e le features identificate se opportunamente validate potrebbero risultare un importante strumento non invasivo di ausilio per il radioterapista per valutare nel breve periodo gli effetti a lungo periodo del trattamento e quindi poter modificare parametri di cura al fine di raggiungere uno stato desiderato del tumore.

Ribosome Biogenesis and cell cycle regulation: Effect of RNA Polymerase III inhibition

In cycling cells positive stimuli like nutrient, growth factors and mitogens increase ribosome biogenesis rate and protein synthesis to ensure both growth and proliferation. In contrast, under stress situation, proliferating cells negatively modulate ribosome production to reduce protein synthesis and block cell cycle progression. The main strategy used by cycling cell to coordinate cell proliferation and ribosome biogenesis is to share regulatory elements, which participate directly in ribosome production and in cell cycle regulation. In fact, there is evidence that stimulation or inhibition of cell proliferation exerts direct effect on activity of the RNA polymerases controlling the ribosome biogenesis, while several alterations in normal ribosome biogenesis cause changes of the expression and the activity of the tumor suppressor p53, the main effector of cell cycle progression inhibition. The available data on the cross-talk between ribosome biogenesis and cell proliferation have been until now obtained in experimental model in which changes in ribosome biogenesis were obtained either by reducing the activity of the RNA polymerase I or by down-regulating the expression of the ribosomal proteins. The molecular pathways involved in the relationship between the effect of the inhibition of RNA polymerase III (Pol III) activity and cell cycle progression have been not yet investigated. In eukaryotes, RNA Polymerase III is responsible for transcription of factors involved both in ribosome assembly (5S rRNA) and rRNA processing (RNAse P and MRP).Thus, the aim of this study is characterize the effects of the down-regulation of RNA Polymerase III activity, or the specific depletion of 5S rRNA. The results that will be obtained might lead to a deeper understanding of the molecular pathway that controls the coordination between ribosome biogenesis and cell cycle, and might give useful information about the possibility to target RNA Polymerase III for cancer treatment.

Cáncer y tratamiento oncológico: Representaciones sociales de la población general, el paciente oncológico y miembros del equipo de salud

Se realizaron tres estudios cualitativos que tuvieron como propósito conocer las representaciones que ha construido la población general, los pacientes oncológicos y los profesionales de la salud, sobre el cáncer, la quimioterapia y el trasplante de médula ósea y realizar un análisis sobre las semejanzas y diferencias entre ellos. Se realizó en la ciudad de Bogotá (Colombia) con 55 personas: 20 pacientes con cáncer en proceso de trasplante de médula ósea, 20 personas no diagnosticadas con cáncer y 15 personas que trabajan en la atención de pacientes con cáncer. Se realizó una entrevista en profundidad con todos los participantes y asociaciones libres, clásicas y por sustitución sobre las palabras “cáncer”, “quimioterapia” y “trasplante de médula”. Los datos conseguidos se analizaron a la luz de la Teoría de las Representaciones Sociales (TRS). El análisis de la información siguió la técnica de análisis cualitativo de contenido para encontrar significados simbólicos y construir, denominar y definir categorías. Para los tres grupos el cáncer es una enfermedad terrible, que puede llevar a la muerte. El personal de salud y la población general creen que la enfermedad genera terror, angustia y miedo. Los pacientes tienen conciencia de la gravedad y del temor consecuente por una enfermedad que lo cambia todo, produce sufrimiento, dolor, obliga a depender de alguien y puede conducir a la muerte. El personal de salud considera que los pacientes lo pueden vivir como un castigo y la población general que puede ser la consecuencia de estilos de vida poco saludables. Para todos, la quimioterapia es un tratamiento para la enfermedad, que por un lado presenta efectos colaterales difíciles y visibles y que producen sentimientos negativos de temor y de angustia y al mismo tiempo constituye una opción y posibilidad de curación. El Trasplante de Médula Ósea representa para todos una oportunidad.

Synthesis and surface modification of silver and gold nanoparticles. Nanomedicine applications against Glioblastoma Multiforme.

In the last decades noble metal nanoparticles (NPs) arose as one of the most powerful tools for applications in nanomedicine field and cancer treatment. Glioblastoma multiforme (GBM), in particular, is one of the most aggressive malignant brain tumors that nowadays still presents a dramatic scenario concerning median survival. Gold nanorods (GNRs) and silver nanoparticles (AgNPs) could find applications such as diagnostic imaging, hyperthermia and glioblastoma therapy. During these three years, both GNRs and AgNPs were synthesized with the “salt reduction” method and, through a novel double phase transfer process, using specifically designed thiol-based ligands, lipophilic GNRs and AgNPs were obtained and separately entrapped into biocompatible and biodegradable PEG-based polymeric nanoparticles (PNPs) suitable for drug delivery within the body. Moreover, a synergistic effect of AgNPs with the Alisertib drug, were investigated thanks to the simultaneous entrapment of these two moieties into PNPs. In addition, Chlorotoxin (Cltx), a peptide that specifically recognize brain cancer cells, was conjugated onto the external surface of PNPs. The so-obtained novel nanosystems were evaluated for in vitro and in vivo applications against glioblastoma multiforme. In particular, for GNRs-PNPs, their safety, their suitability as optoacoustic contrast agents, their selective laser-induced cells death and finally, a high tumor retention were all demonstrated. Concerning AgNPs-PNPs, promising tumor toxicity and a strong synergistic effect with Alisertib was observed (IC50 10 nM), as well as good in vivo biodistribution, high tumor uptake and significative tumor reduction in tumor bearing mice. Finally, the two nanostructures were linked together, through an organic framework, exploiting the click chemistry azido-alkyne Huisgen cycloaddition, between two ligands previously attached to the NPs surface; this multifunctional complex nanosystem was successfully entrapped into PNPs with nanoparticles’ properties maintenance, obtaining in this way a powerful and promising tool for cancer fight and defeat.

Metodi computazionali per l'annotazione di genomi e proteomi

Il progresso tecnologico nel campo della biologia molecolare, pone la comunità scientifica di fronte all’esigenza di dare un’interpretazione all’enormità di sequenze biologiche che a mano a mano vanno a costituire le banche dati, siano esse proteine o acidi nucleici. In questo contesto la bioinformatica gioca un ruolo di primaria importanza. Un nuovo livello di possibilità conoscitive è stato introdotto con le tecnologie di Next Generation Sequencing (NGS), per mezzo delle quali è possibile ottenere interi genomi o trascrittomi in poco tempo e con bassi costi. Tra le applicazioni del NGS più rilevanti ci sono senza dubbio quelle oncologiche che prevedono la caratterizzazione genomica di tessuti tumorali e lo sviluppo di nuovi approcci diagnostici e terapeutici per il trattamento del cancro. Con l’analisi NGS è possibile individuare il set completo di variazioni che esistono nel genoma tumorale come varianti a singolo nucleotide, riarrangiamenti cromosomici, inserzioni e delezioni. Va però sottolineato che le variazioni trovate nei geni vanno in ultima battuta osservate dal punto di vista degli effetti a livello delle proteine in quanto esse sono le responsabili più dirette dei fenotipi alterati riscontrabili nella cellula tumorale. L’expertise bioinformatica va quindi collocata sia a livello dell’analisi del dato prodotto per mezzo di NGS ma anche nelle fasi successive ove è necessario effettuare l’annotazione dei geni contenuti nel genoma sequenziato e delle relative strutture proteiche che da esso sono espresse, o, come nel caso dello studio mutazionale, la valutazione dell’effetto della variazione genomica. È in questo contesto che si colloca il lavoro presentato: da un lato lo sviluppo di metodologie computazionali per l’annotazione di sequenze proteiche e dall’altro la messa a punto di una pipeline di analisi di dati prodotti con tecnologie NGS in applicazioni oncologiche avente come scopo finale quello della individuazione e caratterizzazione delle mutazioni genetiche tumorali a livello proteico.

Synthese und Charakterisierung von Polymeren mit peptidischen Seitenketten

Die Forschung im Bereich der Drug Delivery-Systeme konzentriert sich auf biokompatible und wenig immunogene Trägermoleküle. Eine Klasse vielversprechender Trägersysteme stellen Peptid basierte Polymere dar, die neben einer hohen Biokompatibilität auch eine Sensitivität gegenüber externen Einflüssen aufweisen. Der zwitterionische Charakter von Aminosäuren und Peptiden verhindert die Adsorption von Serumproteinen und ein „antifouling“ Verhalten kann festgestellt werden, sodass diese Moleküle für den Einsatz als Wirkstoffträgersystem sehr geeignet scheinen. In Kombination mit einer bürstenartigen Struktur entstehen Systeme mit einer einzigartigen Peptidarchitektur, die sich durch eine hohe Dichte funktioneller Gruppen für Konjugationsreaktionen auszeichnen und deren formabhängige Zellaufnahme sie besonders attraktiv für die Anwendung als „Nanocarrier“ macht.rnrnDas zwitterionische Poly-(ε-N-Methacryloyl-L-Lysin) (Mw = 721,000 g∙mol 1) wurde durch freie radikalische Polymerisation dargestellt und seine Konformation in Abhängigkeit von Ionenstärke und pH-Wert untersucht. Die Biokompatibilität des Systems konnte durch Toxizitätstests und dynamische Lichtstreuung in humanem Blutserum nachgewiesen werden. Zusammen mit der vernachlässigbaren unspezifischen Aufnahme in dendritische Zellen aus Knochenmark erfüllt das System damit alle Bedingungen, die an ein polymeres Wirkstoffträgersystem gestellt werden. Darüber hinaus können Komplexe des Polymers mit DNA in Gegenwart von divalenten Metallionen für die Gentransfektion verwendet werden.rnrnDurch Kopplung von ε-N-Methacryloyl-L-Lysin mit der Elastin-ähnlichen Polypeptid Pentasequenz Valin-Prolin-Glycin-Glycin-Glycin konnte ein Hexapeptid-Makromonomer dargestellt werden, welches anschließend mittels „grafting through“ Polymerisation zur Polymerbürste umgesetzt wurde. Die wurmartige Struktur der Polymerbürsten wurde in AFM-Aufnahmen gezeigt und eine hohe Kettensteifigkeit der Polymerbürsten über dynamische und statische Lichtstreuung nachgewiesen. Zirkulardichroismus-Messungen lieferten Informationen über struktur-, salz- und temperaturabhängige Veränderungen der Konformation. Toxizitätstests und dynamische Lichtstreuung in humanem Blutserum bestätigten die erwartete Biokompatibilität.rnrnBasierend auf zwei Elastin-ähnlichen Polypeptiden mit ähnlicher Peptidsequenz wurden insgesamt vier unterschiedliche Makromonomere mit jeweils 20 Pentapeptid-Wiederholungseinheiten dargestellt. Über anschließende „grafting through“ Polymerisation entstanden molekulare Bürstenmoleküle mit variierenden externen funktionellen Gruppen, die für zukünftige Konjugationsreaktionen verwendet werden können. Der Einfluss von Ionenstärke und Temperatur auf die Konformation der Makromonomere und Polymere wurde mittels Zirkulardichroismus- und Trübungskurven-Messungen untersucht und ein starker Einfluss der hohen Seitenkettendichte auf das Verhalten der Polymerbürsten wurde festgestellt. Über dynamische Lichtstreuung konnte ein von den externen funktionellen Gruppen abhängiges Aggregationsverhalten in humanem Blutserum nachgewiesen werden.rnrnDie in dieser Arbeit synthetisierten Polymerbürsten mit peptidischen Seitenketten stellen damit biokompatible und vielversprechende Trägersysteme für die Konjugation mit Biomolekülen dar, die zukünftig als Drug Delivery-Systeme ihren Einsatz finden können.rn

TBX3-Mutationsanalysen und Konstruktion einer Zelllinie für TBX2-Inhibitorscreenings

Die nahe verwandten T-box Transkriptionsfaktoren TBX2 und TBX3 werden in zahlreichen humanen Krebsarten überexprimiert, insbesondere in Brustkrebs und Melanomen. Die Überexpression von TBX2 und TBX3 hat verschiedene zelluläre Effekte, darunter die Unterdrückung der Seneszenz, die Förderung der Epithelialen-Mesenchymalen Transition sowie invasive Zellmotilität. Im Gegensatz dazu führt ein Funktionsverlust von TBX3 und der meisten anderen humanen T-box-Gene zu haploinsuffizienten Entwicklungsdefekten. Durch Sequenzierung des Exoms von Brustkrebsproben identifizierten Stephens et al. fünf verschiedene Mutationen in TBX3, welche allesamt die DNA-bindende T-box-Domäne betrafen. Die In-Frame-Deletion N212delN wurde zweimal gefunden. Aus der Anhäufung der Mutationen innerhalb der T-box-Domäne wurde geschlossen, dass TBX3 bei Brustkrebs ein Treibergen ist. Da Mutationen innerhalb der T-box-Domäne im Allgemeinen zu einem Funktionsverlust führen, aber die onkogene Aktivität von TBX3 meist auf eine Überexpression zurückzuführen ist, wurden die potentiellen Treibermutationen hinsichtlich einer verminderten oder gesteigerten TBX3-Funktion geprüft. Getestet wurden zwei In-Frame Deletionen, eine Missense- sowie eine Frameshift-Mutante bezüglich der DNA-Bindung in vitro und der Zielgen-Repression in Zellkultur. Zusätzlich wurde eine in silico Analyse der im The Cancer Genome Atlas (TCGA) gelisteten somatischen TBX-Brustkrebsmutationen durchgeführt. Sowohl die experimentelle als auch die in silico Analyse zeigten, dass die untersuchten Mutationen vorwiegend zum Verlust der TBX3-Funktion führen. Um den Mechanismus der Genrepression durch TBX3 besser zu verstehen, wurden weitere TBX3-Mutanten bezüglich ihrer Wirkung auf die p21-Promotoraktivität (p21-Luc-Reporter und endogene p21-Expression) analysiert. Wildtypische p21-Luc-Repression zeigten die zwei Mutationen S674A (Phosphorylierung) und D275K (SUMOylierung), welche posttranslationale Modifikationen verhindern, sowie die Interaktion mit dem Tumorsuppressor Rb1 unterbindende M302A/V304A-Mutation. Erstaunlicherweise war die endogene p21-Repression dieser Mutanten stärker als die des wildtypischen TBX3-Proteins. Alle drei Mutationen führten zu einer Stabilisierung des TBX3-Proteins. Die ursprünglich in Patienten mit Ulna-Mamma Syndrom identifizierte, DNA-bindungsdefekte Y149S-Mutante konnte weder p21-Luc noch endogenes p21 reprimieren. Mutationen in potentiellen Interaktionsdomänen für die Bindung der Co-Repressoren Groucho und C-terminalem Bindeprotein zeigten sowohl auf p21-Luc als auch auf endogenes p21-Gen wildtypische Repressoraktivität, so dass diese Co-Repressoren in COS-7-Zellen wahrscheinlich nicht an der Repression dieses Gens beteiligt sind. Da TBX2 und TBX3 interessante Ziele zur direkten Krebsbekämpfung darstellen, sollte ein zelluläres Reportersystem zur Identifikation TBX2-inhibierender, pharmakologisch aktiver Substanzen etabliert werden. Dazu sollte eine stabile Zelllinie mit vom p21-Promotor reguliertem d2EGFP-Reporter und Doxyzyklin-induzierbarem TBX2-Protein erzeugt werden, da ektopische Expression von TBX2 genetische Instabilität und Toxizität induzieren kann. In dieser Zelllinie sollte die TBX2-Expression zur Reduktion der d2EGFP-Fluoreszenz führen. Zur Erzeugung der Zelllinie wurden die folgenden drei Konstrukte Schritt-für-Schritt stabil in das Genom der Zielzelllinie COS-7 integriert: pEF1alpha-Tet3G, pTRE3G-TBX2 und p21-d2EGFP. Während die Herstellung der doppelt stabilen COS-7-Zelllinie gelang, scheiterte die Herstellung der dreifach stabilen Zelllinie.

Lineage-specific transcription factor aberrations in AML

Transcription factors play a key role in the commitment of hematopoietic stem cells to differentiate into specific lineages [78]. This is particularly important in that a block in terminal differentiation is the key contributing factor in acute leukemias. This general theme of the role of transcription factors in differentiation may also extend to other tissues, both in terms of normal development and cancer. Consistent with the role of transcription factors in hematopoietic lineage commitment is the frequent finding of aberrations in transcription factors in AML patients. Here, we intend to review recent findings on aberrations in lineage-restricted transcription factors as observed in patients with acute myeloid leukemia (AML).

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

Chemotherapy-induced neutropenia is a major risk factor for infection-related morbidity and mortality and also a significant dose-limiting toxicity in cancer treatment. Patients developing severe (grade 3/4) or febrile neutropenia (FN) during chemotherapy frequently receive dose reductions and/or delays to their chemotherapy. This may impact the success of treatment, particularly when treatment intent is either curative or to prolong survival. In Europe, prophylactic treatment with granulocyte-colony stimulating factors (G-CSFs), such as filgrastim (including approved biosimilars), lenograstim or pegfilgrastim is available to reduce the risk of chemotherapy-induced neutropenia. However, the use of G-CSF prophylactic treatment varies widely in clinical practice, both in the timing of therapy and in the patients to whom it is offered. The need for generally applicable, European-focused guidelines led to the formation of a European Guidelines Working Party by the European Organisation for Research and Treatment of Cancer (EORTC) and the publication in 2006 of guidelines for the use of G-CSF in adult cancer patients at risk of chemotherapy-induced FN. A new systematic literature review has been undertaken to ensure that recommendations are current and provide guidance on clinical practice in Europe. We recommend that patient-related adverse risk factors, such as elderly age (≥65 years) and neutrophil count be evaluated in the overall assessment of FN risk before administering each cycle of chemotherapy. It is important that after a previous episode of FN, patients receive prophylactic administration of G-CSF in subsequent cycles. We provide an expanded list of common chemotherapy regimens considered to have a high (≥20%) or intermediate (10-20%) risk of FN. Prophylactic G-CSF continues to be recommended in patients receiving a chemotherapy regimen with high risk of FN. When using a chemotherapy regimen associated with FN in 10-20% of patients, particular attention should be given to patient-related risk factors that may increase the overall risk of FN. In situations where dose-dense or dose-intense chemotherapy strategies have survival benefits, prophylactic G-CSF support is recommended. Similarly, if reductions in chemotherapy dose intensity or density are known to be associated with a poor prognosis, primary G-CSF prophylaxis may be used to maintain chemotherapy. Clinical evidence shows that filgrastim, lenograstim and pegfilgrastim have clinical efficacy and we recommend the use of any of these agents to prevent FN and FN-related complications where indicated. Filgrastim biosimilars are also approved for use in Europe. While other forms of G-CSF, including biosimilars, are administered by a course of daily injections, pegfilgrastim allows once-per-cycle administration. Choice of formulation remains a matter for individual clinical judgement. Evidence from multiple low level studies derived from audit data and clinical practice suggests that some patients receive suboptimal daily G-CSFs; the use of pegfilgrastim may avoid this problem.

Natural products as leads for anticancer drug discovery: discovery of new chemotypes of microtubule stabilizers through reengineering of the epothilone scaffold

Epothilones are bacterial macrolides with potent microtubule-stabilizing and antiproliferative activity, which have served as successful lead structures for the discovery of several clinical candidates for cancer treatment. Overall, seven epothilone-type agents have been advanced to clinical evaluation in humans so far and one of these has been approved by the FDA in 2007 for clinical use in breast cancer patients. Notwithstanding these impressive numbers, however, the structural diversity represented by the collection of epothilone analogs that have been (or still are) investigated clinically is rather limited and their individual structures show little divergence from the original natural product leads. In contrast, we have elaborated a series of epothilone-derived macro-lactones, whose overall structural features significantly deviate from those of the natural epothilone scaffold and thus define new structural families of microtubule-stabilizing agents. Key elements of our hypermodification strategy are the change of the natural epoxide geometry from cis to trans, the incorporation of conformationally constrained side chains, the removal of the C(3)-hydroxyl group, and the replacement of C(12) with nitrogen. The latter modification leads to aza-macrolides that may be described as 'non-natural natural products'.

The Search for Low Energy Conformational Families of Small Peptides: Searching for Active Conformations of Small Peptides in the Absence of a Known Receptor

Breast cancer is the most common cancer among women. Tamoxifen is the preferred drug for estrogen receptor-positive breast cancer treatment, yet many of these cancers are intrinsically resistant to tamoxifen or acquire resistance during treatment. Therefore, scientists are searching for breast cancer drugs that have different molecular targets. Previous work revealed that 8-mer and cyclic 9-mer peptides inhibit breast cancer in mouse and rat model systems, interacting with an unknown receptor, while peptides smaller than eight amino acids did not inhibit breast cancer. We have shown that the use of replica exchange molecular dynamics predicts structure and dynamics of active peptides, leading to the discovery of smaller peptides with full biological activity. These simulations identified smaller peptide analogs with a conserved turn, a β-turn formed in the larger peptides. These analogs inhibit estrogen-dependent cell growth in a mouse uterine growth assay, a test showing reliable correlation with human breast cancer inhibition. We outline the computational methods that were tried and used with the experimental information that led to the successful completion of this research.

Computational Design and Experimental Discovery of an Anti-estrogenic Peptide Derived from Alpha-Fetoprotein

Breast cancer is the most common cancer among women, and tamoxifen is the preferred drug for estrogen receptor-positive breast cancer treatment. Many of these cancers are intrinsically resistant to tamoxifen or acquire resistance during treatment. Consequently, there is an ongoing need for breast cancer drugs that have different molecular targets. Previous work has shown that 8-mer and cyclic 9-mer peptides inhibit breast cancer in mouse and rat models, interacting with an unsolved receptor, while peptides smaller than eight amino acids did not. We show that the use of replica exchange molecular dynamics predicts the structure and dynamics of active peptides, leading to the discovery of smaller peptides with full biological activity. Simulations identified smaller peptide analogues with the same conserved reverse turn demonstrated in the larger peptides. These analogues were synthesized and shown to inhibit estrogen-dependent cell growth in a mouse uterine growth assay, a test showing reliable correlation with human breast cancer inhibition.